Testing the waters

About 4% of European patents are opposed and, although the actual number of patents opposed has been declining, the annual number of oppositions filed at the European Patent Office (EPO) seems relatively consistent at around 3,000 to 4,000, since total granted patents are rising. In 2017, 3.7% of granted European patents were opposed, and the EPO issued 4,070 opposition decisions, of which 73% were upheld in amended form or as granted.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Europe

Final call: Who are the world’s best in-house counsel?

16 January 2026 A first-of-its-kind project by sister title WIPR aims to highlight the world’s leading in-house intellectual property counsel—and it needs your help.

Europe

Italian medtech startup beats larger US rival in UPC dispute

15 January 2026 Case between AorticLab and Emboline has implications for UPC playbook in terms of requesting security for costs, and conditional counterclaims.

Europe

Bayer secures key Denmark ruling as Xarelto faces expiry pressure

13 January 2026 As the drug moves deeper into its post-exclusivity phase, a Nordic decision highlights the value of secondary patents, presumption of validity, and interim relief when a drug's core patents expire.

More features

Fed Circ overturns PTAB decision in $83.4m DNA case

AI is transforming top 100 innovators, shows index

Novartis win blocks generics relitigating $7.8bn heart drug patent

Rooted in rights: Lessons from plant patent infringement and invalidity cases

Skinny labels, big stakes: SCOTUS lines up the case of the year

Final call: Who are the world’s best in-house counsel?

Speciality pharma firm stumbles on bid to enforce Belbuca ruling

Italian medtech startup beats larger US rival in UPC dispute

Testing the waters

More on this story

Editor's picks

Editor's picks

More features